Many RAS pathway inhibitors, including pan-RAF inhibitors, have shown significant anti-
tumor activities in both solid and hematological tumors. The pan-RAF inhibitor, TAK-580, is a …

Abstract RAS/RAF/MEK/ERK pathway inhibitors exhibit significant anti-tumor effects against
various tumor types, including multiple myeloma (MM), and they are predicted to play a …

The identification of signaling pathways critical to myeloma growth and progression has
yielded an array of novel agents with clinical activity. Multiple myeloma (MM) growth is IL-6 …

2506 Background: RO5126766 is a potent RAF and MEK inhibitor with activity in xenografts
models of RAS and RAF-mutated cancers. We present data from the RAS/RAF-mutated …

Direct therapeutic targeting of oncogenic RAS is currently still impossible due to lack of
suitable pharmacological inhibitors. Because specific blockade of druggable RAS effectors …

LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and
occupies both protomers in RAF dimers. Biochemical and cellular analyses revealed that …

Introduction. The activity of BET inhibitors in several models human hematologic disorders,
including multiple myeloma (MM) has recently been demonstrated. Exposure of cancer cells …

Background: Activating mutations in the MAPK pathway are common in many solid tumors.
RAF kinases play a key role in this pathway and represent a valid target for therapy. This …

Patients with relapsed and refractory multiple myeloma have a poor prognosis. The mitogen-
activated protein kinase (MAPK) pathway has been implicated in the pathogenesis of …

Background: In the US in 2021, invasive melanoma will account for an estimated 106,000
new cases and> 7,000 deaths. Somatic mutations that activate the MAPK signaling pathway …